

HR 3327

Drug Price Transparency for Medicare Patients Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 18, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 19, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/3327>

Sponsor

Name: Rep. Rooney, Francis [R-FL-19]

Party: Republican • **State:** FL • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Lipinski, Daniel [D-IL-3]	D · IL		Jul 10, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 19, 2019
Ways and Means Committee	House	Referred To	Jun 18, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jun 18, 2019)

Drug Price Transparency for Medicare Patients Act of 2019

This bill provides statutory authority for the Centers for Medicare & Medicaid Services rule titled "Medicare and Medicaid Programs; Regulation to Require Drug Pricing Transparency," published on May 10, 2019. The rule requires direct-to-consumer television advertisements for covered drugs and biologics under Medicare and Medicaid to include the list price of a 30-day supply or for a typical course of treatment, if the list price is at least \$35 per month. The rule takes effect July 9, 2019.

Actions Timeline

- **Jun 19, 2019:** Referred to the Subcommittee on Health.
- **Jun 18, 2019:** Introduced in House
- **Jun 18, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.